Kalymin 60 N (Pyridostigmine Bromide)

Pyridostigmine bromide reversibly blocks the enzyme acetylcholinesterase, which normally degrades acetylcholine. By inhibiting this enzyme, the drug raises acetylcholine levels at neuromuscular junctions, leading to stronger muscle contractions and faster bowel movements without affecting the central nervous system.

The appropriate dose of Kalymin 60 N is determined by the prescribing clinician based on the patient’s condition, severity, age, renal function, and response to therapy. Dosage adjustments are made individually; patients should follow the prescriber’s instructions precisely.

Safety data for pyridostigmine bromide in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Kalymin 60 N (pyridostigmine bromide) is a reversible, peripherally acting cholinesterase inhibitor, offering a predictable onset and duration suitable for chronic management of myasthenia gravis. Compared with agents like neostigmine, pyridostigmine has a longer half‑life and fewer central nervous system effects, making it preferred for long‑term outpatient use.

Store Kalymin 60 N at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, excessive heat, and direct sunlight to maintain potency throughout its shelf life.

Kalymin 60 N is taken orally, usually with water. The tablet should be swallowed whole and not crushed or chewed unless specifically directed by a healthcare provider. Dosing times are spaced according to the prescriber’s schedule to maintain steady drug levels.

The most serious risks include cholinergic crisis, which can cause severe muscle weakness and respiratory failure, as well as profound bradycardia, bronchospasm, and rare allergic reactions such as anaphylaxis. Prompt medical attention is required if any of these symptoms develop.

Kalymin 60 N is contraindicated in patients with known hypersensitivity to pyridostigmine or any excipients, those with severe asthma or chronic obstructive pulmonary disease prone to bronchospasm, and individuals with uncontrolled cardiac conduction disorders. Clinicians should evaluate each patient’s medical history before prescribing.